Clinical trials: Movement Abnormalities
Tourette's Disorder
Safety and Tolerability Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder
The goal of the current trial is to obtain long term efficacy, safety and tolerability data of once weekly aripiprazole in children and adolescents with Tourette's Disorder.
- Trial name
- NCT01416441
- Testing
- Aripiprazole
- Where
- 80 sites in United States, Bulgaria and 8 more
- Volunteers
- 170 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Tourette Syndrome
Thalamic Deep Brain Stimulation for the Treatment of Refractory Tourette Syndrome
This research is being performed to try to understand if the use of deep brain stimulation or DBS can treat the symptoms of Tourette syndrome that do not respond well to current medications.
- Trial name
- NCT01817517
- Testing
- Medtronic Activa Deep Brain Stimulation System
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Johns Hopkins University
Parkinson's Disease, Musculoskeletal Pain
Repetitive Transcranial Magnetic Stimulation for Musculoskeletal Pain in Patients With Parkinson's Disease
Pain is an increasingly recognized non-motor symptom of Parkinson's disease (PD), with significant prevalence and negative impact on the quality of life of patients.
- Conditions
- Parkinson's Disease, Musculoskeletal Pain, Repetitive Transcranial Magnetic Stimulation, Primary Motor Cortex
- Trial name
- NCT05537597
- Testing
- active M1-rTMS
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Second Affiliated Hospital of Soochow University
Parkinson Disease
Varenicline for Gait and Balance Impairment in Parkinson Disease
The purpose of this study is to determine if varenicline is effective in improving gait and balance impairment in patients with Parkinson disease.
- Trial name
- Chantix-PD (NCT01341080)
- Testing
- Varenicline, Sugar pill
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Rush University Medical Center
Parkinson's Disease
Video Based Mindfulness Based Stress Reduction
To evaluate the feasibility of a video based mindfulness intervention for stress reduction and to evaluate the cortisol response in persons with PD and their caregivers.
- Trial name
- vMBSR (NCT02705586)
- Testing
- Mindfulness
- Where
- 2 sites in United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Huntington Disease
Study of WVE-003 in Patients With Huntington's Disease
This is a Phase 1b/2a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of WVE-003 in adult patients with early-manifest HD who…
- Trial name
- NCT05032196
- Testing
- SAD: 30mg WVE-003, SAD: 60mg WVE-003, SAD: 90mg WVE-003
- Where
- 23 sites in Australia, Canada and 8 more
- Volunteers
- 47 people
- Sponsor
- Wave Life Sciences USA, Inc.
Parkinson's Disease, Isolated Dystonia
Chronic Effects of DBS in Parkinson's Disease and Dystonia
The purpose of this study is to use an investigational device to record brain activity for 12-24 months following surgical implantation of deep brain stimulation (DBS) systems.
- Trial name
- Activa PC+S (NCT01934296)
- Testing
- Activa PC+S
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of California, San Francisco
Lewy Body Dementia, Parkinson Disease
Anti-Diabetic Medications to Fight PD and LBD
The purpose of this study is to test the hypothesis that DPP4 inhibitors and SGLT2 inhibitors are well tolerated and have beneficial neurological effects, specifically for Parkinson's disease and Lewy body dementia.
- Trial name
- NCT06263673
- Testing
- Sitagliptin, Dapagliflozin
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Mayo Clinic
Idiopathic Parkinson's Disease
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
The purpose of this study was to evaluate the safety and potential benefits of CERE-120 in the treatment of Parkinson's disease.
- Trial name
- NCT00985517
- Testing
- CERE-120: Adeno-Associated Virus Delivery of Neurturin
- Where
- 11 sites in United States
- Volunteers
- 57 people
- Sponsor
- Sangamo Therapeutics
Dementia, Cognitive Impairment, Mild
Cognitive Stimulation Therapy for Dementia: A Two-Armed Pragmatic Trial
Cognitive Stimulation Therapy (CST) is an evidence-based non-pharmacological group therapy shown to benefit people with mild to moderate dementia.
- Conditions
- Dementia, Cognitive Impairment, Mild, Dementia, Vascular, Dementia, Mixed
- Trial name
- NCT05860127
- Testing
- Referral for Cognitive Stimulation Therapy, No change to Standard of Care
- Where
- 2 sites in United States
- Volunteers
- 133 people
- Sponsor
- University of Massachusetts, Amherst
Huntington's Disease
A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease
The primary purpose of the study is to evaluate the safety and tolerability of SAGE-718 softgel lipid capsule in participants with Huntington's Disease (HD)
- Trial name
- NCT05655520
- Testing
- SAGE-718
- Where
- 43 sites in United States, Australia and 2 more
- Volunteers
- 153 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Parkinson's Disease
Cognitive Rehabilitation for PD
To investigate the effectiveness of a novel compensatory cognitive rehabilitation program for individuals with Parkinson's disease (PD) and mild cognitive impairment (MCI).
- Trial name
- CogSMART-PD (NCT03335150)
- Testing
- CogSMART-PD, Supportive Care
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- VA Office of Research and Development
Idiopathic Parkinson's Disease
An Open-Label Extension Trial to Assess the Safety and Tolerability of Long Term Treatment of Rotigotine in Subjects With Idiopathic Parkinson's Disease
The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of rotigotine in subjects with idiopathic PD.
- Trial name
- NCT00505687
- Testing
- Rotigotine
- Where
- 26 sites in United States, Austria and 6 more
- Volunteers
- 186 people
- Sponsor
- UCB Pharma
Parkinson Disease
A Clinical Study Evaluating Efficacy of Pirepemat on Falls Frequency in Patients With Parkinson's Disease (PD)
This is a Phase 2b study investigating the efficacy and safety of pirepemat as adjunct therapy on falls frequency in patients with Parkinson disease. Pirepemat is taken for 84 days.
- Trial name
- NCT05258071
- Testing
- Pirepemat
- Where
- 37 sites in France, Germany and 4 more
- Volunteers
- 104 people
- Sponsor
- Integrative Research Laboratories AB
Parkinson's Disease, Dyskinesia
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
The purpose of this study is to test multiple doses of sarizotan to establish a dose with maximal safety and efficacy for treating treatment associated dyskinesia in Parkinson's disease participants.
- Trial name
- NCT00105521
- Testing
- Sarizotan
- Where
- 32 sites in United States
- Volunteers
- 398 people
- Sponsor
- EMD Serono
Dementia With Lewy Bodies (DLB)
A Study of E2020 in Patients With Dementia With Lewy Bodies (DLB), Followed by a Long-term Extension Phase
The purpose of this study is to confirm the efficacy of E2020 in patients with dementia with Lewy bodies (DLB).
- Trial name
- NCT01278407
- Testing
- Donepezil 5 mg, Donepezil 10 mg
- Where
- 56 sites in Japan
- Volunteers
- 142 people
- Sponsor
- Eisai Co., Ltd.
Wilson's Disease
A Phase I/II Study of VTX-801 in Adult Patients With Wilson's Disease
The objectives of this clinical trial are to assess, for up to 5 years, the safety, tolerability and pharmacological activity of a single ascending doses of VTX-801, a gene therapy, administered intravenously (IV) to adult…
- Trial name
- GATEWAY (NCT04537377)
- Testing
- VTX-801
- Where
- 10 sites in United States, Denmark and 2 more
- Volunteers
- 4 people
- Sponsor
- Vivet Therapeutics SAS
Parkinson Disease
Pramipexole Conversion to Ropinirole Controlled Release (CR)
A conversion study of Mirapex (pramipexole) to Requip (ropinirole) controlled release (CR) in patients with Parkinson's disease to determine the appropriate conversion ratio and side effects related to the drug.
- Trial name
- NCT00275275
- Testing
- Requip PR, Mirapex
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Rajesh Pahwa, MD
REM Behavior Disorder, Parkinsonism
Efficacy and Tolerability of Ramelteon in Patients With Rapid Eye Movement (REM) Behavior Disorder and Parkinsonism
Parkinson's disease (PD) is the second most common neurodegenerative disorder of the elderly that affects a million patients in US. Sleep dysfunction impacts up to 90% of PD patients.
- Trial name
- NCT00745030
- Testing
- Rozerem
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Northwestern University
Parkinson's Disease
Effect of Paracetamol on Opicapone Pharmacokinetics in Healthy Volunteers
Single-centre, open-label, randomised, two-way cross-over study consisting of 2 periods separated by a washout period of 14 days or more.
- Trial name
- NCT02305017
- Testing
- BIA 9-1067, Paracetamol
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.